Addlife ökade omsättningen med 11% under fjärde kvartalet 2024, organisk tillväxt exklusive valutapå...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report.
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent ap...
IPU ramp-up delayed: we cut '25e-'26e revenue by 44-33% UPF partnerships opens a large new segment T...
Analyst Group initiates equity research coverage on Genetic Analysis AS (“Genetic Analysis” or the “...
Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer t...
Redeye provides an initial comment on the Q4 2024 report from Serstech.
Redeye comments on Verve Group’s Q4 2024 results, which came in stronger than expected across the bo...
Føroya Banki reported a soft Q4, as profit before loan losses landed at DKK 46m, DKK 8m (6%) below o...
Redeye provides a research update following the Q4 report published by Lipum earlier today.
- Adj. EBIT 31% vs cons, 51% vs ABG - Order backlog +10% y-o-y, slightly weaker than expected - We e...
Redeye comments on Alligator Bioscience’s 24-month survival numbers, which are superior to historica...
Redeye comments on yesterday’s news from Nitro Games, announcing that Netflix has canceled its proje...
'25 guidance ~50% below (likely due to delayed ramp-up of IPU volumes) One new design (~2k units), o...
Även om vi bibehåller vår positiva syn på Elon inför 2025 och framåt har vi sänkt våra förväntningar...
